AU · rank #5 · 2026-10-23
SHL
XETRA · EUR · $52.45B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.815 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 6 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $45.40 | +8.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +22.45% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.05 |
| Gross margin TTM | +39.0% |
| 52w high | $48.53 |
| Market cap (USD) | $52.45B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Siemens Healthineers is a global medical-devices group in imaging, radiotherapy and diagnostics, with Imaging and Precision Therapy driving growth while Diagnostics remains soft.
Rationale
The stock screens well for analyst_upside because consensus still shows ~8.7% price upside, 19 analysts are broadly aligned, and recent EPS revisions, strong book-to-bill, and a 33.1% earnings surprise support the estimate cycle.
Material risks
- 1Diagnostics weakness in China could keep dragging revenue and sentiment, especially since management now expects roughly 80% of the segment’s full-year decline from that market.
- 2The FY2026 revenue guide was cut to 3.5–4.0% and the company lacks sole-supplier status, so hospital capex timing and competition from GE HealthCare and Philips can blunt the upside case.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.